PTC Therapeutics (NASDAQ:PTCT) Director Sells $945,732.14 in Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) Director Allan Steven Jacobson sold 11,801 shares of the stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $80.14, for a total transaction of $945,732.14. Following the transaction, the director owned 17,451 shares in the company, valued at approximately $1,398,523.14. This trade represents a 40.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Allan Steven Jacobson also recently made the following trade(s):

• On Tuesday, November 25th, Allan Steven Jacobson sold 14,199 shares of PTC Therapeutics stock. The shares were sold at an average price of $83.55, for a total value of $1,186,326.45.
• On Friday, October 3rd, Allan Steven Jacobson sold 12,000 shares of PTC Therapeutics stock. The stock was sold at an average price of $65.00, for a total transaction of $780,000.00.
• On Thursday, August 28th, Allan Steven Jacobson sold 1,667 shares of PTC Therapeutics stock. The shares were sold at an average price of $50.15, for a total transaction of $83,600.05.
• On Thursday, August 28th, Allan Steven Jacobson sold 1,667 shares of PTC Therapeutics stock. The stock was sold at an average price of $50.15, for a total transaction of $83,600.05.

PTC Therapeutics Stock Performance

Shares of PTCT stock traded up $3.32 during mid-day trading on Wednesday, reaching $86.25. 15,474,693 shares of the company’s stock traded hands, compared to its average volume of 1,201,735. PTC Therapeutics, Inc. has a 12 month low of $35.95 and a 12 month high of $87.50. The firm has a 50 day moving average price of $67.91 and a two-hundred day moving average price of $56.23. The firm has a market capitalization of $6.92 billion, a PE ratio of 12.37 and a beta of 0.60.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.19) by $1.39. PTC Therapeutics had a negative return on equity of 106.31% and a net margin of 35.65%.The business had revenue of $211.01 million during the quarter, compared to analyst estimates of $177.42 million. During the same quarter in the previous year, the company posted ($1.39) earnings per share. PTC Therapeutics’s revenue for the quarter was up 7.2% on a year-over-year basis. PTC Therapeutics has set its FY 2025 guidance at EPS. As a group, equities analysts expect that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of PTCT. Smartleaf Asset Management LLC lifted its position in PTC Therapeutics by 101.3% during the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 236 shares during the last quarter. Optiver Holding B.V. lifted its holdings in shares of PTC Therapeutics by 96.5% in the 3rd quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 249 shares during the last quarter. Comerica Bank lifted its stake in shares of PTC Therapeutics by 868.5% in the 3rd quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 469 shares during the last quarter. Quantbot Technologies LP boosted its stake in PTC Therapeutics by 545.5% during the first quarter. Quantbot Technologies LP now owns 652 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 551 shares during the period. Finally, PNC Financial Services Group Inc. raised its position in PTC Therapeutics by 84.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 320 shares during the period.

Analyst Upgrades and Downgrades

PTCT has been the subject of a number of recent analyst reports. Truist Financial upped their price target on shares of PTC Therapeutics from $80.00 to $86.00 and gave the stock a “buy” rating in a research report on Tuesday, July 29th. TD Cowen raised their price target on PTC Therapeutics from $50.00 to $63.00 and gave the company a “hold” rating in a report on Wednesday, November 5th. Jefferies Financial Group boosted their price objective on PTC Therapeutics from $63.00 to $77.00 and gave the company a “buy” rating in a research report on Tuesday, October 28th. Royal Bank Of Canada increased their target price on PTC Therapeutics from $70.00 to $82.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. Finally, Barclays boosted their price target on PTC Therapeutics from $46.00 to $68.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 5th. Ten research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $75.40.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.